Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
24 participants
INTERVENTIONAL
2025-02-01
2026-02-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This is important, because short-sightedness now starts at a younger age and worsens faster than in the past. Many people are at risk of permanently losing their eyesight in middle-age because of short-sightedness.
The researchers plan to use red LED light, which is safe to use. Red-light treatment improves the blood flow at the back of the eye, in a layer called "choroid", which can be measured on eye-scans. The team have done a study with healthy adults, which showed that red-light is safe and gently improves the blood flow at the back of the eye. In adults, this has no effect on myopia, because their eyes are fully grown. In children, red-light may slow down myopia, and in this project, the researchers want to find out which level of red-light is needed to have this effect. The researchers will ask 24 children age 5-12 years to use red-light for three minutes twice a day for three months. Three will be 4 groups of children, and each group will use a different level of brightness. The researchers will measure the eye length and the thickness of the choroid at the start and 1 and 3 months later and compare the change in eye length between the different groups.
In practice, children will need to use the treatment for several years. The researchers will use the results of this study to prepare a longer study with more children.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Real-world Study of 650nm Low-intensity Single-wavelength Red Light for Children and Adolescents
NCT05832723
Red Light Intervention for Myopia Prevention
NCT04825769
Effect of Low-level Red-light on Ultra-high Myopia
NCT06738095
650nm Low-level Red-light for Myopia Control and Prevention in Children
NCT05786586
Minimum Power and Frequency of Repeated Low-level Red-light to Effectively Control Myopia Progression
NCT06717048
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SEQUENTIAL
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intensity 1
Children will use red-light of the lowest intensity, twice daily for 3 minutes, at home
Red Light (PDT)
Red LED light
Intensity 2
Children will use red-light of low intensity, but slightly higher than in the Intensity 1 arm, twice daily for 3 minutes, at home
Red Light (PDT)
Red LED light
Intensity 3
Children will use red-light of medium intensity, slightly higher than in the Intensity 2 arm, twice daily for 3 minutes, at home
Red Light (PDT)
Red LED light
Intensity 4
Children will use red-light of medium intensity, slightly higher than in the Intensity 3 arm, twice daily for 3 minutes, at home
Red Light (PDT)
Red LED light
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Red Light (PDT)
Red LED light
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* best-corrected visual acuity 0.1 logMAR or better in both eyes
Exclusion Criteria
* previous or current myopia-modifying treatment
* abnormal ocular refractive anatomy or previous intraocular or ocular surgery
5 Years
12 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University College, London
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Annegret Dahlmann-Noor, PhD
Role: PRINCIPAL_INVESTIGATOR
UCL
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University College London
London, London, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Annegret Dahlmann-Noor, PhD
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EDGE 166432
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.